ACE2 and infection: The advantage of targeting ACE2 levels is highlighted by the fact that the protective immunity gained from vaccination or previous SARS-CoV-2 infection is short term, and the phenotypic instability of the virus contributes to the high frequency of new variants that can evade vaccine- and/or infection-derived immunity [36].